Copyright © 2003 by the European Society of Cardiology.
Clinical research
Parathyroid hormone and left ventricular hypertrophy
a Department of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
b Institute of Community Medicine, University of Tromsø, Tromsø, Norway
c Department of Clinical Chemistry, University Hospital of North Norway, Tromsø, Norway
* Correspondence to: Farahnaz N. Saleh, Department of Internal Medicine, University Hospital of North Norway, 9038 Tromsø, Norway. Tel: +47 77628090; Fax: +47 77626863
E-mail address: farahnaz.saleh{at}unn.no
Received 20 January 2003; revised 14 August 2003; accepted 11 September 2003
Abstract
Aims A relation between left ventricular hypertrophy and parathyroid hormone (PTH) has been described in patients with end stage renal disease and secondary hyperparathyroidism. In vitro studies indicate a hypertrophic effect of PTH on cardiomyocytes. The purpose of this study was to examine the relation between PTH and left ventricular hypertrophy in a general population.
Methods and results The fourth Tromsø study (1994–1995) included 27 159 subjects. 2700 had serum PTH measurement and left ventricular mass by height (LVMH) estimated with M-mode echocardiography. Among these, 980 males and 1060 females were without known cardiovascular disease or valvular heart disease and did not use blood pressure medication. In this group, using a multiple linear regression model, body mass index (BMI), followed by systolic blood pressure, were found to be the strongest predictors of LVMH. In males older than 59 years and females younger than 60 years, PTH was a significant and positive predictor of LVMH (P<0.05). The relation between PTH and LVMH was not linear. There was a sharp increase in LVMH (both unadjusted and adjusted for age, BMI, and systolic blood pressure) in the upper PTH percentiles with the breaking point being the 95 percentile for men and the 98 percentile for women. Subjects in these upper PTH ranges had 12–17% higher adjusted LVMH than those in the lower 10% of the PTH range. This effect was not related to serum calcium level. If examining separately those with PTH levels within ±2SD from the mean, no relation between PTH and LVMH was found.
Conclusions PTH is an independent predictor of LVMH in males older than 59 years and females younger than 60 years. This effect is only seen when PTH is substantially elevated and may then be involved in cardiac pathophysiology.
Key Words: Echocardiography • Left ventricularhypertrophy • Parathyroid hormone • Blood pressure • Body mass index
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Hagstrom, P. Hellman, T. E. Larsson, E. Ingelsson, L. Berglund, J. Sundstrom, H. Melhus, C. Held, L. Lind, K. Michaelsson, et al. Plasma Parathyroid Hormone and the Risk of Cardiovascular Mortality in the Community Circulation, June 2, 2009; 119(21): 2765 - 2771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Covic, P. Kothawala, M. Bernal, S. Robbins, A. Chalian, and D. Goldsmith Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1506 - 1523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Adeney, D. S. Siscovick, J. H. Ix, S. L. Seliger, M. G. Shlipak, N. S. Jenny, and B. R. Kestenbaum Association of Serum Phosphate with Vascular and Valvular Calcification in Moderate CKD J. Am. Soc. Nephrol., February 1, 2009; 20(2): 381 - 387. [Full Text] [PDF]
|
|
|
|
|
|
D. E. Wallis, S. Penckofer, and G. W. Sizemore The "Sunshine Deficit" and Cardiovascular Disease Circulation, September 30, 2008; 118(14): 1476 - 1485. [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Cheng, D. O. Young, Y. Huang, J. A. Delmez, and D. W. Coyne A Randomized, Double-Blind, Placebo-Controlled Trial of Niacinamide for Reduction of Phosphorus in Hemodialysis Patients Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1131 - 1138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Raggi and M. Kleerekoper Contribution of Bone and Mineral Abnormalities to Cardiovascular Disease in Patients with Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 836 - 843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Reppe, L. Stilgren, B. Abrahamsen, O. K. Olstad, F. Cero, K. Brixen, L. S. Nissen-Meyer, and K. M. Gautvik Abnormal muscle and hematopoietic gene expression may be important for clinical morbidity in primary hyperparathyroidism Am J Physiol Endocrinol Metab, May 1, 2007; 292(5): E1465 - E1473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. E. Cingolani and I. L. Ennis Sodium-Hydrogen Exchanger, Cardiac Overload, and Myocardial Hypertrophy Circulation, March 6, 2007; 115(9): 1090 - 1100. [Full Text] [PDF]
|
|
|
|
 |
|
 S. S Schleithoff, A. Zittermann, G. Tenderich, H. K Berthold, P. Stehle, and R. Koerfer Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am. J. Clinical Nutrition, April 1, 2006; 83(4): 754 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Kestenbaum, J. N. Sampson, K. D. Rudser, D. J. Patterson, S. L. Seliger, B. Young, D. J. Sherrard, and D. L. Andress Serum Phosphate Levels and Mortality Risk among People with Chronic Kidney Disease J. Am. Soc. Nephrol., February 1, 2005; 16(2): 520 - 528. [Abstract] [Full Text] [PDF]
|
|